Phoenicia BioScience & Phoenicia Therapeutics

Our company, funded by SBIR/STTR grants, develops therapeutics from bench to bedside. The lead candidate, a therapy for serious orphan blood diseases, co-developed with the NIH, Therapeutics for Rare or Neglected Diseases Program (TRND), is de-risked for safety in other patients and for efficacy in nonhuman primates. The goal is to conduct our FDA approved clinical trial of the lead and license it and a pipeline to complete development.